DRDO anti-COVID drug gets DCGI emergency use nod
The 2-DG comes in powder form in sachet and is taken orally by dissolving it in water.
New Delhi: The Drugs Controller General of India has approved an anti-COVID oral drug, developed by DRDO, for emergency use as adjunct therapy in moderate to severe coronavirus patients, the defence ministry said on Saturday.
It said clinical trials of the drug 2-deoxy-D-glucose (2-DG) showed that it helps in faster recovery of hospitalised patients and reduces supplemental oxygen dependence.
The drug has been developed by Institute of Nuclear Medicine and Allied Sciences (INMAS), a leading laboratory of Defence Research and Development Organisation (DRDO), in collaboration with Dr Reddy's Laboratories in Hyderabad.
The 2-DG comes in powder form in sachet and is taken orally by dissolving it in water.
Read also: VINS Bioproducts bags DCGI nod to begin VINCOV-19 trials
'On May 01, DCGI granted permission for emergency use of this drug as adjunct therapy in moderate to severe COVID-19 patients. Being a generic molecule and analogue of glucose, it can be easily produced and made available in plenty in the country,' the ministry said in a statement.
'It accumulates in the virus infected cells and prevents virus growth by stopping viral synthesis and energy production. Its selective accumulation in virally-infected cells makes this drug unique,' the ministry said.
